Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Fibroblasts in cancer

Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Microenvironmental regulation of metastasis

Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

Drug resistance in targeted cancer therapies with RAF inhibitors

Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 36

Cancer cells and adaptive explanations

Germain, P. (2012) · Biology & Philosophy · doi:10.1007/s10539-012-9334-2 · Cited by 41

Adipose-derived stem cells induced EMT-like changes in H358 lung cancer cells.

Park, Y. M., Yoo, S. H., & Kim, S.-H. (2013) · PubMed · Cited by 36

Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment

Holton, A. B., Sinatra, F. L., Kreahling, J., Conway, A. J., Landis, D. A., & Altiok, S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169797 · Cited by 35

Study on drug screening multicellular model for colorectal cancer constructed by three-dimensional bioprinting technology

Wang, P., Sun, L., Li, C., Jin, B., Yang, H., Wu, B., & Mao, Y. (2023) · International Journal of Bioprinting · doi:10.18063/ijb.694 · Cited by 37

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Shan, K. S., Rehman, T. U., Ivanov, S., Domingo, G. C., & Raez, L. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010624 · Cited by 42

High‐throughput sequencing of the melanoma genome

Kunz, M., Dannemann, M., & Kelso, J. F. (2012) · Experimental Dermatology · doi:10.1111/exd.12054 · Cited by 36

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors

Onion, D., Argent, R. H., Reece-Smith, A. M., Craze, M. L., Pineda, R. G., Clarke, P. A., Ratan, H. L., Parsons, S. L., Lobo, D. N., Duffy, J. P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0598 · Cited by 35

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b ][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor

Zhan, Z., Xia, P., Liu, Q., Chen, F., Ji, Y., Yao, S., Xi, Y., Lin, Y., Chen, T., Xu, Y., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.076 · Cited by 35

Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures

Mosaad, E. M. O., Chambers, K., Futrega, K., Clements, J. A., & Doran, M. R. (2018) · BMC Cancer · doi:10.1186/s12885-018-4473-8 · Cited by 35

Targeting Metabolic Cross Talk between Cancer Cells and Cancer-Associated Fibroblasts

Jung, J. G., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_12 · Cited by 38

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer

Novoplansky, O., Fury, M. G., Prasad, M., Yegodayev, K. M., Zorea, J., Cohen, L., Pelossof, R., Cohen, L., Katabi, N., Cecchi, F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32170 · Cited by 36

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype

Bian, Y., Teper, Y., Griner, L. A. M., Aiken, T. J., Shukla, V., Guha, R., Shinn, P., Xin, H.-W., Pflicke, H., Powers, A. S., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1011 · Cited by 35

Reverse intratumor bacteria-induced gemcitabine resistance with carbon nanozymes for enhanced tumor catalytic-chemo therapy

Xi, J., Wang, Y., Gao, X. J., Huang, Y., Chen, J., Chen, Y., Fan, L., & Gao, L. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101395 · Cited by 36

Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells

Kawashima, N., Ishikawa, Y., Kim, J. H., Ushijima, Y., Akashi, A., Yamaguchi, Y., Hattori, H., Nakashima, M., Ikeno, S., Kihara, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29304-6 · Cited by 38

Unraveling cell-to-cell signaling networks with chemical biology

Gartner, Z. J., Prescher, J. A., & Lavis, L. D. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2391 · Cited by 33

Single‐cell RNA sequencing to explore cancer‐associated fibroblasts heterogeneity: “Single” vision for “heterogeneous” environment

Zhang, X., Zhu, R., Yu, D., Wang, J., Yan, Y., & Xu, K. (2023) · Cell Proliferation · doi:10.1111/cpr.13592 · Cited by 35

Artesunate Nanoplatform Targets the Serine–MAPK Axis in Cancer‐Associated Fibroblasts to Reverse Photothermal Resistance in Triple‐Negative Breast Cancer

Zheng, D., Yan, J., Liu, X., Zhang, Z., Jin, A., Zhao, Y., Bai, L., Quan, M.-Y., Qi, X., Fu, B., et al. (2025) · Advanced Materials · doi:10.1002/adma.202502617 · Cited by 34

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma

Parker, R., Vella, L. J., Xavier, D., Amirkhani, A., Parker, J., Cebon, J. S., & Molloy, M. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00095 · Cited by 33

Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support

Boutter, J., Huang, Y., Marovca, B., Vonderheit, A., Grotzer, M. A., Eckert, C., Cario, G., Wollscheid, B., Horváth, P., Bornhauser, B. C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2572 · Cited by 35

Melanoma Mutagenesis and Aberrant Cell Signaling

Bello, D. M., Ariyan, C. E., & Carvajal, R. D. (2013) · Cancer Control · doi:10.1177/107327481302000404 · Cited by 36

Varying effects of EGF, HGF and TGFβ on formation of invadopodia and invasiveness of melanoma cell lines of different origin

Makowiecka, A., Simiczyjew, A., Nowak, D., & Mazur, A. J. (2016) · European Journal of Histochemistry · doi:10.4081/ejh.2016.2728 · Cited by 34

The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells

Jenkins, M. H., Croteau, W., Mullins, D. W., & Brinckerhoff, C. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.05.007 · Cited by 37

The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma

Liu, X., Wu, J., Qin, H., & Xu, J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0565-2 · Cited by 36

Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells

Chang, L., Hu, Y. W., Fu, Y., Zhou, T., You, J., Du, J., Zheng, L., Cao, J., Ying, M., Dai, X., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.001 · Cited by 34

Omental Tissue-Mediated Tumorigenesis of Gastric Cancer Peritoneal Metastases

Kersy, O., Loewenstein, S., Lubezky, N., Sher, O., Simon, N. B., Klausner, J. M., & Lahat, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01267 · Cited by 34

The pan-cancer landscape of netrin family reveals potential oncogenic biomarkers

Hao, W., Yu, M., Lin, J., Liu, B., Xing, H., Yang, J., Sun, D., Chen, F., Jiang, M., Tang, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62117-5 · Cited by 33

Targeting Epiregulin in the Treatment-Damaged Tumor Microenvironment Diminishes Therapeutic Resistance

Wang, C., Long, Q., Fu, Q., Xu, Q., Fu, D., Li, Y., Gao, L., Guo, J., Zhang, X., Lam, E. W. ‐., et al. (2021) · Oncogene · doi:10.1038/s41388-022-02476-7 · Cited by 37

Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition

Shi, X., Wang, M., Zhang, Y., Guo, X., Liu, M., Zhou, Z., Zhao, Y., He, R., Gao, Y., Liu, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104352 · Cited by 34

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model

Hayakawa, H., Ichihara, E., Ohashi, K., Ninomiya, T., Yasugi, M., Takata, S., Sakai, K., Matsumoto, K., Takigawa, N., Tanimoto, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12284 · Cited by 36

Mutant p53—a potential player in shaping the tumor–stroma crosstalk

Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz071 · Cited by 35

A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth

Lal-Nag, M., McGee, L., Guha, R., Lengyel, E., Kenny, H. A., & Ferrer, M. (2017) · SLAS Discovery · doi:10.1177/2472555216687082 · Cited by 33

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF

Ishikawa, D., Takeuchi, S., Nakagawa, T., Sano, T., Nakade, J., Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062104 · Cited by 33

MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells

Boccaccio, C., Luraghi, P., & Comoglio, P. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1088 · Cited by 34

Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor

Oyanagi, J., Kojima, N., Sato, H., Higashi, S., Kikuchi, K., Sakai, K., Matsumoto, K., & Miyazaki, K. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.04.009 · Cited by 33

β-Catenin Inhibitor ICAT Modulates the Invasive Motility of Melanoma Cells

Domingues, M. J., Rambow, F., Job, B., Papon, L., Liu, W., Larue, L., & Bonaventure, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0920 · Cited by 33

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations

Obaid, N., Bedard, K., & Huang, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030585 · Cited by 37

Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation

Owusu, B. Y., Thomas, S., Venukadasula, P. K. M., Han, Z., Janetka, J. W., Galemmo, R. A., & Klampfer, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18260 · Cited by 33

Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

Xiao, J., Egger, M. E., McMasters, K. M., & Hao, H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4583-3 · Cited by 35

The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers

Donnelly, D. M., Aung, P. P., & Jour, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.014 · Cited by 32

Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways

Zervantonakis, I. K., Poskus, M. D., Scott, A. L., Selfors, L. M., Lin, J., Dillon, D. A. R., Pathania, S., Sorger, P. K., Mills, G. B., & Brugge, J. S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000648117 · Cited by 34

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts

Zhu, K., Lv, Z., Xiong, J., Zheng, H., Zhang, S., Jin, H., Yu, L., Li, Z., Zhang, J., Li, C., et al. (2021) · Aging · doi:10.18632/aging.202547 · Cited by 33

Tumor microenvironment-based screening repurposes drugs targeting cancer stem cells and cancer-associated fibroblasts

Lee, P.-J., Ho, C., Ho, H. H., Chen, W.-J., Lin, C.-H., Lai, Y., Juan, Y., Chu, W.-C., Lee, J.-H., Su, S., et al. (2021) · Theranostics · doi:10.7150/thno.62676 · Cited by 36

RAS pathway regulation in melanoma

Mahi, A. A., & Ablain, J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049229 · Cited by 33

The future of targeted kinase inhibitors in melanoma

Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 37

Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges

Kamal, M. A., Mandour, Y. M., El‐Aziz, M. K. A., Stein, U., & Tayebi, H. M. E. (2022) · Molecules · doi:10.3390/molecules27175537 · Cited by 35

Mechanobiology of solid tumors

Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166555 · Cited by 33

Resistance to targeted therapies: a role for microRNAs?

Migliore, C., & Giordano, S. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.002 · Cited by 33

Functional and therapeutic relevance of hepatocyte growth factor/c‐MET signaling in synovial sarcoma

Imura, Y., Nakai, T., Yamada, S., Outani, H., Takenaka, S., Hamada, K., Araki, N., Itoh, K., Yoshikawa, H., & Naka, N. (2016) · Cancer Science · doi:10.1111/cas.13092 · Cited by 33

Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model

Cai, W., Ratnayake, R., Gerber, M. H., Chen, Q.-Y., Yu, Y., Derendorf, H., Trevino, J. G., & Luesch, H. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0647-0 · Cited by 33

Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)

Ugolini, A., Kenigsberg, M., Rak, A., Vallée, F., Houtmann, J., Lowinski, M., Capdevila, C., Khider, J., Albert, E., Martinet, N., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00280 · Cited by 33

Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways

Liu, D., Che, X., & Wu, G. (2024) · Biomarker Research · doi:10.1186/s40364-023-00545-x · Cited by 34

Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside

Wang, Z., Wang, M., Dong, B., Wang, Y., Ding, Z., & Shen, S. (2025) · Nature Communications · doi:10.1038/s41467-025-66376-6 · Cited by 46

Discovery of novel type II c-Met inhibitors based on BMS-777607

Zhang, W., Ai, J., Shi, D., Xia, P., Ji, Y., Liu, J., Geng, M., & Li, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.056 · Cited by 32

New therapeutic strategies for BRAF mutant colorectal cancers.

Corcoran, R. B. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.076 · Cited by 32

The third dimension: new developments in cell culture models for colorectal research

Pereira, J., Awatade, N. T., Loureiro, C. A., Matos, P., Amaral, M. D., & Jordan, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2258-2 · Cited by 32

Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology

Conway, J. R. W., Vennin, C., Cazet, A., Herrmann, D., Murphy, K. J., Warren, S. C., Wullkopf, L., Boulghourjian, A., Zaratzian, A., Silva, A. M. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17177-5 · Cited by 32

Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers

Sun, Y., Wang, R., Qiao, M., Yan-chun, X., Guan, W., & Wang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26433 · Cited by 32

Stress responses in stromal cells and tumor homeostasis

Vitale, I., Manic, G., Galassi, C., & Galluzzi, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.004 · Cited by 33

The Interplay between Colon Cancer Cells and Tumour-Associated Stromal Cells Impacts the Biological Clock and Enhances Malignant Phenotypes

Fuhr, L., Abreu, M., Carbone, A., El‐Athman, R., Bianchi, F., Laukkanen, M. O., Mazzoccoli, G., & Relógio, A. (2019) · Cancers · doi:10.3390/cancers11070988 · Cited by 35

Cancer Drug Resistance

Link, W. (2019) · Springer eBooks · doi:10.1007/978-3-030-18722-4_3 · Cited by 33

Identification of FPR3 as a Unique Biomarker for Targeted Therapy in the Immune Microenvironment of Breast Cancer

Qi, J., Liu, Y., Hu, J., Lu, L., Dou, Z., Dai, H., Wang, H., & Yang, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.593247 · Cited by 32

Gastric cancer cell death analyzed by live cell imaging of spheroids

Alzeeb, G., Arzur, D., Trichet, V., Talagas, M., Corcos, L., & Jossic-Corcos, C. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-05426-1 · Cited by 33

Bcl-2 family inhibitors sensitize human cancer models to therapy

Valentini, E., Martile, M. D., Brignone, M., Caprio, M. D., Manni, I., Chiappa, M., Sergio, I., Chiacchiarini, M., Bazzichetto, C., Conciatori, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05963-1 · Cited by 35

Genetics of melanoma

Wangari‐Talbot, J., & Chen, S. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2012.00330 · Cited by 34

NPPB is a novel candidate biomarker expressed by cancer‐associated fibroblasts in epithelial ovarian cancer

Lawrenson, K., Grün, B., Lee, N., Mhawech-Fauceglia, P. Y., Kan, J., Swenson, S. D., Lin, Y. G., Pejovic, T. B., Millstein, J., & Gayther, S. A. (2014) · International Journal of Cancer · doi:10.1002/ijc.29092 · Cited by 32

Mécanismes de résistance aux inhibiteurs de BRAF

Charles, J., Martel, C., de Fraipont, F., Leccia, M. ‐., Robert, C., & Busser, B. (2014) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2014.06.021 · Cited by 36

Secretome Analysis: Reading Cellular Sign Language to Understand Intercellular Communication

Wu, W., & Krijgsveld, J. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100692 · Cited by 36

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma

Schmid, S., Siano, M., Joerger, M., Rodriguez, R., Müller, J., & Früh, M. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.11.008 · Cited by 31

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors

Tang, C. Z., Jardim, D. L. F., Falchook, G. S., Hess, K. R., Fu, S., Wheler, J. J., Zinner, R., Naing, A., Tsimberidou, A. M., Gagliato, D. D. M., et al. (2013) · Oncoscience · doi:10.18632/oncoscience.3 · Cited by 31

Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells

Kozar, I., Cesi, G., Margue, C., Philippidou, D., & Kreis, S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.04.005 · Cited by 31

Progression-Related Loss of Stromal Caveolin 1 Levels Mediates Radiation Resistance in Prostate Carcinoma via the Apoptosis Inhibitor TRIAP1

Ketteler, J., Panic, A., Reis, H., Wittka, A., Maier, P., Herskind, C., Yagüe, E., Jendrossek, V., & Klein, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030348 · Cited by 31

Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas

Su, J., Long, W., Ma, Q., Xiao, K., Yang, L., Xiao, Q., Peng, G., Yuan, J., & Liu, Q. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01143 · Cited by 30

RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics

Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 33

Intermittent treatment of BRAF V600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge

Kavran, A. J., Stuart, S. A., Hayashi, K. R., Basken, J., Brandhuber, B. J., & Ahn, N. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113535119 · Cited by 31

Computational estimation of quality and clinical relevance of cancer cell lines

Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31

SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity

Alcaraz, L. B., Mallavialle, A., Mollévi, C., Boissière‐Michot, F., Mansouri, H., Simony-Lafontaine, J., Laurent‐Matha, V., Chardès, T., Jacot, W., Turtoï, A., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34345 · Cited by 31

Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers

Sanati, M., Figueroa‐Espada, C. G., Han, E. L., Mitchell, M. J., & Yavari, S. A. (2024) · ACS Nano · doi:10.1021/acsnano.4c11259 · Cited by 33

Melanoma: oncogenic drivers and the immune system.

Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 30

Priming cancer cells for drug resistance: role of the fibroblast niche

Fang, W. B., Yao, M., & Cheng, N. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1300-8 · Cited by 31

Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma

Finisguerra, V., Prenen, H., & Mazzone, M. (2016) · Oncogene · doi:10.1038/onc.2016.36 · Cited by 30

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity

Emery, C. M., Monaco, K., Wang, P., Balak, M. N., Freeman, A. K., Meltzer, J., Delach, S. M., Rakiec, D. P., Ruddy, D. A., Korn, J. M., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0211 · Cited by 30

Reciprocal Reprogramming of Cancer Cells and Associated Mesenchymal Stem Cells in Gastric Cancer

Shamai, Y., Cohn-Alperovich, D., Zohar Yakhini, B., Skorecki, K. L., & Tzukerman, M. (2018) · Stem Cells · doi:10.1002/stem.2942 · Cited by 29

BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/β-catenin signaling

Yang, W., Wu, B., Ma, N., Wang, Y., Guo, J., Zhu, J., & Zhao, S. (2019) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00360-5 · Cited by 30

The Role of MET in Melanoma and Melanocytic Lesions

Zhou, Y., Song, K. Y., & Giubellino, A. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.08.002 · Cited by 30

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma

Savoia, P., Zavattaro, E., & Cremona, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249730 · Cited by 31

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Belli, C., Antonarelli, G., Repetto, M., Bielo, L. B., Crimini, E., & Curigliano, G. (2022) · Cancers · doi:10.3390/cancers14174278 · Cited by 31

Shifting the focus of zebrafish toward a model of the tumor microenvironment

Weiss, J. M., Lumaquin, D., Montal, E. D., Suresh, S., Leonhardt, C.-S., & White, R. M. (2022) · eLife · doi:10.7554/elife.69703 · Cited by 31

Simultaneous Inhibition of the HGF/MET and Erk1/2 Pathways Affect Uveal Melanoma Cell Growth and Migration

Chattopadhyay, C., Grimm, E. A., & Woodman, S. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083957 · Cited by 30

Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAFV600E mutant thyroid cancer cells in 2D and 3D culture

Ingeson-Carlsson, C., Martinez‐Monleon, A., & Nilsson, M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.08.003 · Cited by 33

AKT inactivation causes persistent drug tolerance to EGFR inhibitors

Tetsu, O., Phuchareon, J., Eisele, D. W., Hangauer, M. J., & McCormick, F. P. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.022 · Cited by 31

Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF

Giroux, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.037 · Cited by 30

Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model

Narita, Y., Okamoto, K., Kawada, M. I., Takase, K., Minoshima, Y., Kodama, K., Iwata, M., Miyamoto, N., & Sawada, K. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0667 · Cited by 31

Interaction of molecular alterations with immune response in melanoma

Sloane, R. A. S., Gopalakrishnan, V., Reddy, S. M., Zhang, X., Reuben, A., & Wargo, J. A. (2017) · Cancer · doi:10.1002/cncr.30681 · Cited by 31

Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Hayashi, T., Yamashita, T., Terashima, T., Suda, T., Okada, H., Asahina, Y., Hayashi, T., Hara, Y., Nio, K., Sunagozaka, H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3889-x · Cited by 30

A Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy

Zheng, Y., Bao, J., Zhao, Q., Zhou, T., & Sun, X. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0634 · Cited by 30

Tumor-Associated CD204-Positive Macrophage Is a Prognostic Marker in Clinical Stage I Lung Adenocarcinoma

Sun, Y., & Xu, S. (2018) · BioMed Research International · doi:10.1155/2018/8459193 · Cited by 33

BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1

Grimm, J., Hufnagel, A., Wobser, M., Borst, A., Haferkamp, S., Houben, R., & Meierjohann, S. (2018) · Oncogenesis · doi:10.1038/s41389-018-0082-2 · Cited by 31

Highly efficient microfluidic device for cell trapping and pairing towards cell-cell communication analysis

Zhu, J., Wang, Y., Chen, P., Su, H., Du, W., & Liu, B. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.12.078 · Cited by 30

Systemic therapy of metastatic melanoma: on the road to cure.

Bhatia, S., Tykodi, S. S., Lee, S. M., & Thompson, J. A. (2015) · PubMed · Cited by 30

Abstract 4837: Tumor microenvironment contributes to RAF-inhibitor resistance through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Ronki, M., Du, J., Davis, A., Gould, J., Flaherty, K. T., Ogino, S., Wargo, J. A., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4837 · Cited by 1

Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma

Nickoloff, B. J., & Woude, G. V. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12020 · Cited by 1

FetA gets fat

Bucci, M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1058 · Cited by 2

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134

The stroma's contribution

Donner, A. L. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1055 · Cited by 2